Tucatinib & Trastuzumab Show Promise for Leptomeningeal Metastasis in Breast Cancer

A new combination therapy is offering a measure of hope for patients facing a particularly aggressive form of breast cancer: leptomeningeal metastasis, where the disease has spread to the tissues surrounding the brain and spinal cord. Researchers at The University of Texas MD Anderson Cancer Center have found that a regimen of targeted therapies – tucatinib and trastuzumab – alongside the chemotherapy drug capecitabine, may both improve quality of life and extend survival for some individuals with this advanced condition.

Historically, leptomeningeal metastasis (LM) has been a grim diagnosis, with limited effective treatment options. The challenge lies in delivering therapies that can cross the blood-brain barrier, a protective mechanism that often keeps drugs from reaching the central nervous system. This new approach appears to overcome some of those hurdles, offering a potential lifeline for patients who previously faced few possibilities.

Understanding Leptomeningeal Metastasis

Leptomeningeal metastasis isn’t a primary cancer itself, but rather a complication that arises when cancer cells break away from a primary tumor – in this case, HER2-positive breast cancer – and travel to the cerebrospinal fluid. This fluid cushions the brain and spinal cord. Once there, the cancer cells can spread throughout the central nervous system, causing a range of neurological symptoms. These can include headaches, seizures, weakness, cognitive changes, and even paralysis. MD Anderson explains that treatment for LM is often limited, and outcomes are typically poor.

The Phase II Trial: Results and Context

The findings, published in Nature Cancer, stem from a Phase II clinical trial involving 17 women newly diagnosed with HER2-positive breast cancer that had metastasized to the leptomeninges. Phase II trials are designed to assess the safety and preliminary effectiveness of a treatment. This study wasn’t a randomized controlled trial – meaning there wasn’t a comparison group receiving a different treatment – but rather a single-arm study, comparing the results to historical data.

The median overall survival (OS) for patients treated with the tucatinib, trastuzumab, and capecitabine combination increased to 10 months, a significant improvement compared to the historical average of 4.4 months. Importantly, at the 18-month mark, 41% of the patients in the trial were still alive. Researchers also observed that the disease progression stalled, with a median of seven months before central nervous system progression. Seven out of twelve patients evaluated showed improvements in their neurological deficits.

Rashmi Murthy, M.D., associate professor of Breast Medical Oncology at MD Anderson and lead author of the study, emphasized the clinical significance of the findings. “The combination achieved a clinically meaningful improvement in overall survival compared to historical controls,” she stated. “For these patients, who often face limited treatment options, our results represent a step forward, offering new hope in how we treat and manage leptomeningeal metastasis.”

How the Treatment Works: Targeting HER2

The success of this combination hinges on targeting the HER2 protein. HER2 is a growth-promoting protein that is overexpressed in approximately 20-25% of breast cancers. Tucatinib and trastuzumab are both targeted therapies designed to block the HER2 protein, inhibiting cancer cell growth. Capecitabine, a chemotherapy drug, works by interfering with DNA synthesis, further hindering cancer cell proliferation. The combination aims to attack the cancer cells through multiple pathways, potentially increasing its effectiveness.

Reaching the Brain: Tucatinib’s Unique Ability

A particularly encouraging aspect of the study is that tucatinib was found to reach therapeutic levels in the cerebrospinal fluid. This represents crucial because many drugs struggle to cross the blood-brain barrier. The ability of tucatinib to penetrate this barrier suggests it can directly target cancer cells within the central nervous system. The Nature Cancer study details the pharmacokinetic data confirming this penetration.

Limitations and What the Study Doesn’t Advise Us

It’s crucial to acknowledge the limitations of this study. As a Phase II trial with a small sample size (17 patients) and lacking a control group, the results are considered preliminary. While the improvement in overall survival is promising, it’s based on a comparison to historical data, which can be subject to biases. A larger, randomized controlled trial is needed to confirm these findings and definitively establish the efficacy of the combination therapy. The study also focused specifically on women with HER2-positive breast cancer; it’s unclear whether the treatment would be effective for other types of cancer that metastasize to the leptomeninges.

What Comes Next: Further Research and Clinical Trials

The researchers are continuing to investigate this combination therapy in ongoing clinical trials. The current study (NCT03501979) is registered on ClinicalTrials.gov. Future research will focus on identifying biomarkers that can predict which patients are most likely to benefit from this treatment, and on exploring potential strategies to further enhance its effectiveness. Larger, randomized trials are essential to confirm these initial findings and to establish this combination as a standard of care for HER2-positive breast cancer with leptomeningeal metastasis. The team at MD Anderson is also exploring ways to improve drug delivery to the central nervous system, potentially through the apply of novel drug carriers or other innovative approaches.

For patients and families affected by leptomeningeal metastasis, this research offers a glimmer of hope. While more studies are needed, the initial results suggest that a targeted combination therapy may provide a meaningful improvement in survival and quality of life for some individuals facing this challenging diagnosis. Anyone with concerns about breast cancer or leptomeningeal metastasis should consult with a qualified healthcare professional for personalized advice and treatment options.